MXPA05003302A - Compuestos de piperazina terapeuticos. - Google Patents
Compuestos de piperazina terapeuticos.Info
- Publication number
- MXPA05003302A MXPA05003302A MXPA05003302A MXPA05003302A MXPA05003302A MX PA05003302 A MXPA05003302 A MX PA05003302A MX PA05003302 A MXPA05003302 A MX PA05003302A MX PA05003302 A MXPA05003302 A MX PA05003302A MX PA05003302 A MXPA05003302 A MX PA05003302A
- Authority
- MX
- Mexico
- Prior art keywords
- piperazine compounds
- therapeutic
- hydroxyiminopiperazine compound
- animal
- disclosed
- Prior art date
Links
- 150000004885 piperazines Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- -1 Hydroxyiminopiperazine Compound Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41284702P | 2002-09-24 | 2002-09-24 | |
| PCT/US2003/030185 WO2004029031A2 (en) | 2002-09-24 | 2003-09-24 | Therapeutic piperazine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05003302A true MXPA05003302A (es) | 2005-10-18 |
Family
ID=32043195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05003302A MXPA05003302A (es) | 2002-09-24 | 2003-09-24 | Compuestos de piperazina terapeuticos. |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US7157462B2 (enExample) |
| EP (2) | EP1810970B8 (enExample) |
| JP (1) | JP4560610B2 (enExample) |
| KR (1) | KR20050052514A (enExample) |
| CN (1) | CN100393713C (enExample) |
| AT (2) | ATE356817T1 (enExample) |
| AU (1) | AU2003272685A1 (enExample) |
| BR (1) | BR0314699A (enExample) |
| CA (1) | CA2500113C (enExample) |
| CY (1) | CY1106634T1 (enExample) |
| DE (2) | DE60312544T2 (enExample) |
| DK (1) | DK1562936T3 (enExample) |
| ES (1) | ES2285170T3 (enExample) |
| MX (1) | MXPA05003302A (enExample) |
| NZ (1) | NZ539205A (enExample) |
| PT (1) | PT1562936E (enExample) |
| SI (1) | SI1562936T1 (enExample) |
| WO (1) | WO2004029031A2 (enExample) |
| ZA (1) | ZA200502326B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60234812D1 (de) | 2001-01-29 | 2010-02-04 | Shionogi & Co | Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält |
| US7157462B2 (en) * | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| ES2327684T3 (es) | 2003-07-24 | 2009-11-02 | Euro-Celtique S.A. | Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor. |
| EP1648878B9 (en) * | 2003-07-24 | 2011-03-16 | Euro-Celtique S.A. | Piperidine compounds and pharmaceutical compositions containing them |
| MXPA06001331A (es) * | 2003-08-01 | 2006-05-04 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor. |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| US20070203140A1 (en) * | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| EA200870449A1 (ru) * | 2006-04-19 | 2009-04-28 | Джилл П. Смит | Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008057300A2 (en) * | 2006-10-27 | 2008-05-15 | Redpoint Bio Corporation | Trpvi antagonists and uses thereof |
| EP2142529B1 (en) * | 2007-04-27 | 2013-12-25 | Purdue Pharma LP | Trpv1 antagonists and uses thereof |
| US20090105348A1 (en) * | 2007-10-18 | 2009-04-23 | Harry Fisch | Treatment of migraine headaches using antiestrogens |
| WO2009096701A2 (en) | 2008-01-28 | 2009-08-06 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| JP5438103B2 (ja) | 2008-07-02 | 2014-03-12 | アモーレパシフィック コーポレイション | バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物 |
| CA3012229C (en) | 2008-07-08 | 2020-11-10 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基－雜芳基衍生物及其使用方法 |
| US8921373B2 (en) | 2010-06-22 | 2014-12-30 | Shionogi & Co., Ltd. | Compounds having TRPV1 antagonistic activity and uses thereof |
| JP6130827B2 (ja) | 2011-05-17 | 2017-05-17 | 塩野義製薬株式会社 | ヘテロ環化合物 |
| RS55701B1 (sr) | 2011-06-22 | 2017-07-31 | Purdue Pharma Lp | Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe |
| EP3744715A1 (en) | 2013-11-08 | 2020-12-02 | Incyte Holdings Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| WO2018023017A1 (en) | 2016-07-29 | 2018-02-01 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer |
| US11443441B2 (en) | 2017-02-24 | 2022-09-13 | Brainlab Ag | Deep inspiration breath-hold setup using x-ray imaging |
| US12649744B2 (en) | 2020-12-22 | 2026-06-09 | Pathios Therapeutics Limited | N-(pyridin-2-yl)-6,7,8,9-tetrahydro-5h-5,8-epiminocyclohepta[c]pyridine-10-carboxamide derivatives and similar compounds as GPR65 modulators for the treatment of cancer |
| EP4330258A1 (en) | 2021-04-26 | 2024-03-06 | Pathios Therapeutics Limited | Compounds |
| DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450272A (en) | 1982-05-06 | 1984-05-22 | American Cyanamid Company | Antiatherosclerotic 1-piperazine-thicarboxamides |
| US4439606A (en) | 1982-05-06 | 1984-03-27 | American Cyanamid Company | Antiatherosclerotic 1-piperazinecarbonyl compounds |
| US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US5198459A (en) | 1987-07-11 | 1993-03-30 | Sandoz Ltd. | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents |
| US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
| US6204284B1 (en) | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
| US5232934A (en) | 1992-07-17 | 1993-08-03 | Warner-Lambert Co. | Method for the treatment of psychomotor stimulant addiction |
| DE4234295A1 (de) | 1992-10-12 | 1994-04-14 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| GB9306578D0 (en) | 1993-03-30 | 1993-05-26 | Merck Sharp & Dohme | Therapeutic agents |
| GB9308725D0 (en) | 1993-04-27 | 1993-06-09 | Wyeth John & Brother Ltd | Piperazine derivatives |
| US5461047A (en) | 1993-06-16 | 1995-10-24 | G. D. Searle & Co. | 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use |
| US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| FR2722788B1 (fr) | 1994-07-20 | 1996-10-04 | Pf Medicament | Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant |
| US5556837A (en) | 1994-08-01 | 1996-09-17 | Regeneron Pharmaceuticals Inc. | Methods for treating addictive disorders |
| US5762925A (en) | 1994-11-03 | 1998-06-09 | Sagen; Jacqueline | Preventing opiate tolerance by cellular implantation |
| SK282252B6 (sk) | 1995-01-11 | 2001-12-03 | Samjin Pharmaceutical Co., Ltd. | Piperazínové deriváty a farmaceutický prostriedok s ich obsahom |
| EP0850222B1 (en) | 1996-06-29 | 2003-05-28 | Samjin Pharmaceutical Co., Ltd. | Piperazine derivatives and process for the preparation thereof |
| WO1999007672A1 (en) | 1997-08-05 | 1999-02-18 | Novo Nordisk A/S | Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use |
| DE69943144D1 (de) | 1998-03-31 | 2011-03-03 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
| US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
| WO2000017163A1 (en) | 1998-09-22 | 2000-03-30 | Yamanouchi Pharmaceutical Co., Ltd. | Cyanophenyl derivatives |
| WO2000052001A1 (en) | 1999-03-03 | 2000-09-08 | Samjin Pharmaceutical Co., Ltd. | Piperazine derivatives and process for the preparation thereof |
| US6109269A (en) | 1999-04-30 | 2000-08-29 | Medtronic, Inc. | Method of treating addiction by brain infusion |
| EP1313477A4 (en) | 2000-07-15 | 2004-03-03 | Smithkline Beecham Corp | COMPILATIONS AND METHODS |
| IL153884A0 (en) * | 2000-07-20 | 2003-07-31 | Neurogen Corp | Capsaicin receptor ligands |
| EP1311478B1 (en) | 2000-08-21 | 2006-06-07 | Pacific Corporation | Novel (thio)urea compounds and the pharmaceutical compositions containing the same |
| NZ523882A (en) | 2000-08-21 | 2004-11-26 | Pacific Corp | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| MY138086A (en) | 2001-09-13 | 2009-04-30 | Smithkline Beecham Plc | Novel urea derivative as vanilloid receptor-1 antagonist |
| RS63204A (sr) | 2002-01-17 | 2006-10-27 | Neurogen Corporation | Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina |
| ATE416168T1 (de) | 2002-02-15 | 2008-12-15 | Glaxo Group Ltd | Modulatoren des vanilloidrezeptors |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US20030158188A1 (en) | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| DE60318875T2 (de) | 2002-06-28 | 2009-01-15 | Euro-Celtique S.A. | Therapeutische piperazin-derivate für die behandlung von schmerzen |
| US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| ES2327684T3 (es) | 2003-07-24 | 2009-11-02 | Euro-Celtique S.A. | Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor. |
| EP1648878B9 (en) | 2003-07-24 | 2011-03-16 | Euro-Celtique S.A. | Piperidine compounds and pharmaceutical compositions containing them |
| ES2322907T3 (es) | 2003-12-30 | 2009-07-01 | Euro-Celtique S.A. | Piperazinas utiles para el tratamiento de dolor. |
-
2003
- 2003-09-23 US US10/669,823 patent/US7157462B2/en not_active Expired - Lifetime
- 2003-09-24 DE DE60312544T patent/DE60312544T2/de not_active Expired - Lifetime
- 2003-09-24 DE DE60332562T patent/DE60332562D1/de not_active Expired - Lifetime
- 2003-09-24 CA CA2500113A patent/CA2500113C/en not_active Expired - Fee Related
- 2003-09-24 AT AT03754883T patent/ATE356817T1/de active
- 2003-09-24 MX MXPA05003302A patent/MXPA05003302A/es active IP Right Grant
- 2003-09-24 ES ES03754883T patent/ES2285170T3/es not_active Expired - Lifetime
- 2003-09-24 JP JP2004539882A patent/JP4560610B2/ja not_active Expired - Fee Related
- 2003-09-24 EP EP07104074A patent/EP1810970B8/en not_active Expired - Lifetime
- 2003-09-24 PT PT03754883T patent/PT1562936E/pt unknown
- 2003-09-24 AU AU2003272685A patent/AU2003272685A1/en not_active Abandoned
- 2003-09-24 CN CNB03825297XA patent/CN100393713C/zh not_active Expired - Fee Related
- 2003-09-24 DK DK03754883T patent/DK1562936T3/da active
- 2003-09-24 WO PCT/US2003/030185 patent/WO2004029031A2/en not_active Ceased
- 2003-09-24 BR BR0314699-5A patent/BR0314699A/pt not_active IP Right Cessation
- 2003-09-24 SI SI200330815T patent/SI1562936T1/sl unknown
- 2003-09-24 AT AT07104074T patent/ATE467627T1/de not_active IP Right Cessation
- 2003-09-24 EP EP03754883A patent/EP1562936B1/en not_active Expired - Lifetime
- 2003-09-24 KR KR1020057005096A patent/KR20050052514A/ko not_active Ceased
- 2003-09-24 NZ NZ539205A patent/NZ539205A/en not_active IP Right Cessation
-
2005
- 2005-03-18 ZA ZA200502326A patent/ZA200502326B/en unknown
-
2006
- 2006-11-16 US US11/601,792 patent/US7737148B2/en not_active Expired - Lifetime
-
2007
- 2007-06-04 CY CY20071100730T patent/CY1106634T1/el unknown
-
2008
- 2008-09-29 US US12/240,688 patent/US7855210B2/en not_active Expired - Lifetime
-
2010
- 2010-11-10 US US12/943,739 patent/US20110082152A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004029031A3 (en) | Therapeutic piperazine compounds | |
| ES2295609T3 (es) | Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor. | |
| PT1664016E (pt) | Agentes terapêuticos úteis para tratamento da dor | |
| MXPA05013587A (es) | Agentes terapeuticos utiles para el tratamiento del dolor. | |
| WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
| RU94044436A (ru) | Способы подавления атрофии кожи и влагалища | |
| CY1109037T1 (el) | Πιπεραζινες χρησιμες για θεραπεια πονου | |
| PL1664041T3 (pl) | Przydatne do leczenia bólu związki fenylowo-karboksyamidowe | |
| AU3850600A (en) | Dalda analogs and their use | |
| RU94044454A (ru) | Ингибитор аутоимунных заболеваний | |
| GB0130677D0 (en) | Medicaments and novel compounds | |
| SE9802208D0 (sv) | Novel compounds | |
| GEP20043227B (en) | 5HT1 Antagonists for Antidepressant Therapy | |
| SE9802209D0 (sv) | Novel compounds | |
| BG103512A (en) | Substituted pyramidine compounds and their application | |
| GEP20043231B (en) | Resorcinol Composition | |
| WO2002076400A3 (en) | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease | |
| WO2001007029A3 (en) | Substituted guanidines and the use thereof | |
| AU2002211217A1 (en) | Method of treating stroke | |
| MY133957A (en) | "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor" | |
| MXPA05003633A (es) | 2"-oxo-voruscharina y derivados de la misma. | |
| MX9701528A (es) | Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer. | |
| ES2173044A1 (es) | Glicina, n-(n-l- -glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |